Cholesterol and lipoprotein metabolism and atherosclerosis: Recent advances in reverse cholesterol transport

Helen H. Wang, Gabriella Garruti, Min Liu, Piero Portincasa, David Q.H. Wang

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Atherosclerosis is characterized by lipid accumulation, inflammatory response, cell death and fibrosis in the arterial wall, and is a major pathological basis for ischemic coronary heart disease (CHD), which is the leading cause of morbidity and mortality in the USA and Europe. Intervention studies with statins have shown to reduce plasma LDL cholesterol concentrations and subsequently the risk of developing CHD. However, not all the aggressive statin therapy could decrease the risk of developing CHD. Many clinical and epidemiological studies have clearly demonstrated that the HDL cholesterol is inversely associated with risk of CHD and is a critical and independent component of predicting this risk. Elucidations of HDL metabolism give rise to therapeutic targets with potential to raising plasma HDL cholesterol levels, thereby reducing the risk of developing CHD. The concept of reverse cholesterol transport is based on the hypothesis that HDL displays an cardioprotective function, which is a process involved in the removal of excess cholesterol that is accumulated in the peripheral tissues (e.g., macrophages in the aortae) by HDL, transporting it to the liver for excretion into the feces via the bile. In this review, we summarize the latest advances in the role of the lymphatic route in reverse cholesterol transport, as well as the biliary and the non-biliary pathways for removal of cholesterol from the body. These studies will greatly increase the likelihood of discovering new lipid-lowering drugs, which are more effective in the prevention and therapeutic intervention of CHD that is the major cause of human death and disability worldwide.

Original languageEnglish (US)
Pages (from-to)s27-s42
JournalAnnals of Hepatology
Volume16
DOIs
StatePublished - Nov 1 2017

Fingerprint

Coronary Disease
Atherosclerosis
Cholesterol
Hydroxymethylglutaryl-CoA Reductase Inhibitors
HDL Cholesterol
Lipids
Feces
Bile
LDL Cholesterol
Myocardial Ischemia
Aorta
lipoprotein cholesterol
Epidemiologic Studies
Cause of Death
Fibrosis
Cell Death
Therapeutics
Macrophages
Morbidity
Mortality

Keywords

  • Biliary lipid secretion
  • Cholesterol-lowering drugs
  • Coronary heart disease
  • Intestinal lipid absorption
  • Statins
  • Stroke

ASJC Scopus subject areas

  • Hepatology

Cite this

Cholesterol and lipoprotein metabolism and atherosclerosis : Recent advances in reverse cholesterol transport. / Wang, Helen H.; Garruti, Gabriella; Liu, Min; Portincasa, Piero; Wang, David Q.H.

In: Annals of Hepatology, Vol. 16, 01.11.2017, p. s27-s42.

Research output: Contribution to journalArticle

Wang, Helen H. ; Garruti, Gabriella ; Liu, Min ; Portincasa, Piero ; Wang, David Q.H. / Cholesterol and lipoprotein metabolism and atherosclerosis : Recent advances in reverse cholesterol transport. In: Annals of Hepatology. 2017 ; Vol. 16. pp. s27-s42.
@article{7bcffba7e29e4ef0836988a1f1e659d7,
title = "Cholesterol and lipoprotein metabolism and atherosclerosis: Recent advances in reverse cholesterol transport",
abstract = "Atherosclerosis is characterized by lipid accumulation, inflammatory response, cell death and fibrosis in the arterial wall, and is a major pathological basis for ischemic coronary heart disease (CHD), which is the leading cause of morbidity and mortality in the USA and Europe. Intervention studies with statins have shown to reduce plasma LDL cholesterol concentrations and subsequently the risk of developing CHD. However, not all the aggressive statin therapy could decrease the risk of developing CHD. Many clinical and epidemiological studies have clearly demonstrated that the HDL cholesterol is inversely associated with risk of CHD and is a critical and independent component of predicting this risk. Elucidations of HDL metabolism give rise to therapeutic targets with potential to raising plasma HDL cholesterol levels, thereby reducing the risk of developing CHD. The concept of reverse cholesterol transport is based on the hypothesis that HDL displays an cardioprotective function, which is a process involved in the removal of excess cholesterol that is accumulated in the peripheral tissues (e.g., macrophages in the aortae) by HDL, transporting it to the liver for excretion into the feces via the bile. In this review, we summarize the latest advances in the role of the lymphatic route in reverse cholesterol transport, as well as the biliary and the non-biliary pathways for removal of cholesterol from the body. These studies will greatly increase the likelihood of discovering new lipid-lowering drugs, which are more effective in the prevention and therapeutic intervention of CHD that is the major cause of human death and disability worldwide.",
keywords = "Biliary lipid secretion, Cholesterol-lowering drugs, Coronary heart disease, Intestinal lipid absorption, Statins, Stroke",
author = "Wang, {Helen H.} and Gabriella Garruti and Min Liu and Piero Portincasa and Wang, {David Q.H.}",
year = "2017",
month = "11",
day = "1",
doi = "10.5604/01.3001.0010.5495",
language = "English (US)",
volume = "16",
pages = "s27--s42",
journal = "Annals of Hepatology",
issn = "1665-2681",
publisher = "Mexican Association of Hepatology",

}

TY - JOUR

T1 - Cholesterol and lipoprotein metabolism and atherosclerosis

T2 - Recent advances in reverse cholesterol transport

AU - Wang, Helen H.

AU - Garruti, Gabriella

AU - Liu, Min

AU - Portincasa, Piero

AU - Wang, David Q.H.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Atherosclerosis is characterized by lipid accumulation, inflammatory response, cell death and fibrosis in the arterial wall, and is a major pathological basis for ischemic coronary heart disease (CHD), which is the leading cause of morbidity and mortality in the USA and Europe. Intervention studies with statins have shown to reduce plasma LDL cholesterol concentrations and subsequently the risk of developing CHD. However, not all the aggressive statin therapy could decrease the risk of developing CHD. Many clinical and epidemiological studies have clearly demonstrated that the HDL cholesterol is inversely associated with risk of CHD and is a critical and independent component of predicting this risk. Elucidations of HDL metabolism give rise to therapeutic targets with potential to raising plasma HDL cholesterol levels, thereby reducing the risk of developing CHD. The concept of reverse cholesterol transport is based on the hypothesis that HDL displays an cardioprotective function, which is a process involved in the removal of excess cholesterol that is accumulated in the peripheral tissues (e.g., macrophages in the aortae) by HDL, transporting it to the liver for excretion into the feces via the bile. In this review, we summarize the latest advances in the role of the lymphatic route in reverse cholesterol transport, as well as the biliary and the non-biliary pathways for removal of cholesterol from the body. These studies will greatly increase the likelihood of discovering new lipid-lowering drugs, which are more effective in the prevention and therapeutic intervention of CHD that is the major cause of human death and disability worldwide.

AB - Atherosclerosis is characterized by lipid accumulation, inflammatory response, cell death and fibrosis in the arterial wall, and is a major pathological basis for ischemic coronary heart disease (CHD), which is the leading cause of morbidity and mortality in the USA and Europe. Intervention studies with statins have shown to reduce plasma LDL cholesterol concentrations and subsequently the risk of developing CHD. However, not all the aggressive statin therapy could decrease the risk of developing CHD. Many clinical and epidemiological studies have clearly demonstrated that the HDL cholesterol is inversely associated with risk of CHD and is a critical and independent component of predicting this risk. Elucidations of HDL metabolism give rise to therapeutic targets with potential to raising plasma HDL cholesterol levels, thereby reducing the risk of developing CHD. The concept of reverse cholesterol transport is based on the hypothesis that HDL displays an cardioprotective function, which is a process involved in the removal of excess cholesterol that is accumulated in the peripheral tissues (e.g., macrophages in the aortae) by HDL, transporting it to the liver for excretion into the feces via the bile. In this review, we summarize the latest advances in the role of the lymphatic route in reverse cholesterol transport, as well as the biliary and the non-biliary pathways for removal of cholesterol from the body. These studies will greatly increase the likelihood of discovering new lipid-lowering drugs, which are more effective in the prevention and therapeutic intervention of CHD that is the major cause of human death and disability worldwide.

KW - Biliary lipid secretion

KW - Cholesterol-lowering drugs

KW - Coronary heart disease

KW - Intestinal lipid absorption

KW - Statins

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=85046080199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046080199&partnerID=8YFLogxK

U2 - 10.5604/01.3001.0010.5495

DO - 10.5604/01.3001.0010.5495

M3 - Article

C2 - 29080338

AN - SCOPUS:85046080199

VL - 16

SP - s27-s42

JO - Annals of Hepatology

JF - Annals of Hepatology

SN - 1665-2681

ER -